



SGLT2-Inhibition in patients with Alport syndrome

Jan Boeckhaus, Daniel P. Gale, James Simon, Jie Ding, Yanqin Zhang, Carsten Bergmann, A. Neil Turner, Matthew Hall, John A. Sayer, Shalabh Srivastava, Hee Gyung Kang, Agne Cerkauskaite-Kerpauskiene, Valentine Gillion, Kathleen J. Claes, Bastian Krueger, Jonathan de Fallois, Ulrike Walden, Mira Choi, Markus Schueler, Roman-Ulrich Mueller, Polina Todorova, Bernd Hohenstein, Michael Zeisberg, Tim Friede, Bertrand Knebelmann, Jan Halbritter, Oliver Gross

PII: S2468-0249(24)01942-9

DOI: <https://doi.org/10.1016/j.ekir.2024.09.014>

Reference: EKIR 2995

To appear in: *Kidney International Reports*

Received Date: 23 July 2024

Revised Date: 7 September 2024

Accepted Date: 16 September 2024

Please cite this article as: Boeckhaus J, Gale DP, Simon J, Ding J, Zhang Y, Bergmann C, Turner AN, Hall M, Sayer JA, Srivastava S, Kang HG, Cerkauskaite-Kerpauskiene A, Gillion V, Claes KJ, Krueger B, de Fallois J, Walden U, Choi M, Schueler M, Mueller RU, Todorova P, Hohenstein B, Zeisberg M, Friede T, Knebelmann B, Halbritter J, Gross O, SGLT2-Inhibition in patients with Alport syndrome, *Kidney International Reports* (2024), doi: <https://doi.org/10.1016/j.ekir.2024.09.014>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

SGLT2-Inhibition in patients with Alport syndrome

Jan Boeckhaus^{1,a}, Daniel P. Gale^{2,3}, James Simon⁴, Jie Ding⁵, Yanqin Zhang⁵, Carsten Bergmann⁶, A. Neil Turner⁷, Matthew Hall⁸, John A. Sayer^{9,10,11}, Shalabh Srivastava^{12,13}, Hee Gyung Kang^{14,15}, Agne Cerkauskaitė-Kerpauskienė¹⁶, Valentine Gillion¹⁷, Kathleen J. Claes^{18,19}, Bastian Krueger²⁰, Jonathan de Fallois²⁰, Ulrike Walden²¹, Mira Choi²², Markus Schueler²², Roman-Ulrich Mueller^{23,24}, Polina Todorova²³, Bernd Hohenstein²⁵, Michael Zeisberg¹, Tim Friede²⁶, Bertrand Knebelmann^{27,28}, Jan Halbritter^{22,b} and Oliver Gross^{1,b}

¹Clinic for Nephrology and Rheumatology, University Medical Center Goettingen, Germany

²Department of Renal Medicine, University College London, London, UK
³Department of Renal Medicine, University College London, UK

³National Registry of Rare Kidney Diseases (RaDaR), Bristol, UK

⁴Department of Kidney Medicine, Medical Specialties Institute, Cleveland Clinic, Cleveland, OH, USA

⁵Peking University First Hospital, Department of Pediatrics, No. 1 Xi An Men Da Jie, Beijing, China

⁶Medizinische Genetik Mainz, Limbach Genetics, Mainz, Germany

⁷University of Edinburgh, Edinburgh, UK

⁸Nottingham University Hospitals, Nottingham, UK

⁹Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

¹⁰Renal Services, Newcastle upon Tyne National Health Service Foundation Trust, Newcastle upon Tyne, UK

¹¹National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK

¹²South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK

¹³Newcastle University, Newcastle Upon Tyne, UK

¹⁴Departments of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea

¹⁵Departments of Pediatrics, Seoul National University College of Medicine, Seoul, Korea

¹⁶Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

¹⁷Nephrology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium

¹⁸Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium

¹⁹Department of Microbiology, Immunology, and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium

²⁰Division of Nephrology, Department of Internal Medicine, University of Leipzig Medical Center, Leipzig, Germany.

²¹Paediatric and Adolescent Medicine, University Medical Center Augsburg, Augsburg, Germany

²²Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

²³Department II of Internal Medicine and Center for Rare Diseases Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

²⁴Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.

²⁵Nephrologisches Zentrum Villingen-Schwenningen, Villingen-Schwenningen, Germany

²⁶Department of Medical Statistics, University Medical Center Goettingen

²⁷Faculté de médecine, Université Paris Cité, Paris, France

²⁸Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Service de Néphrologie, Paris, France

^aCorrespondence: Dr. Jan Boeckhaus, Clinic for Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany, Tel: +49 5513960400 Email jan.boeckhaus@med.uni-goettingen.de

^bshared senior authorship

Running head

SGLT2-inhibition in Alport syndrome

1 Abstract

2 Introduction: Large-scale trials showed positive outcomes of sodium–glucose cotransporter-2
3 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD). Whether the use of SGLT2i
4 is safe and effective in patients with the common hereditary CKD Alport syndrome has not
5 yet been investigated specifically in larger cohorts.

6 Methods: This observational, multi-center, international study (NCT02378805) assessed 112
7 patients with Alport syndrome after start of SGLT2i. The study's primary endpoint was
8 change of albuminuria in albumin/gram creatinine from start of therapy.

9 Results: Compared to randomized trials investigating the effect of SGLT2i in CKD, the adult
10 patients in this study were younger (38 ± 14 years) and had a better estimated glomerular
11 filtration rate, eGFR, (63 ± 35 ml/min/1.73m²; n=98). Maximum follow up was 32 months.
12 Compared to baseline, at the first three follow-up visits (months 1 to 3, 4 to 8 and 9 to 15) after
13 initiation of SGLT2i-therapy, a significant reduction of albuminuria in milligrams
14 albumin/gram creatinine (>30%) was observed. Mean loss of eGFR was 9 ± 12 ml/min/1.73 m²
15 almost one year after initiation of SGLT2i-therapy (n=35). At a total of 71 patient-years at risk,
16 0.24 adverse events per patient year on SGLT2i were reported.

17 Conclusion: This study indicates that, additive to RAS-inhibition, SGLT2i have the potential
18 to reduce the amount of albuminuria in patients with Alport syndrome. Future studies are
19 needed to investigate the long-term effects of SGLT2i on CKD progression in patients with
20 Alport syndrome to assess whether the observed reduction in albuminuria translates to a delay
21 in kidney failure.

22

1 **Key words**

2 SGLT2-inhibition; Dapagliflozin; Empagliflozin; Alport syndrome; Albuminuria; sodium–
3 glucose cotransporter-2 inhibitors, *COL4*, kidney failure

4

5

6

Journal Pre-proof

1 Introduction

2 Slowing progression of chronic kidney disease (CKD) has highest priority in nephrology.
3 Recent randomized clinical trials (RCTs) demonstrated the nephroprotective effect of sodium–
4 glucose cotransporter-2 inhibitors (SGLT2i) in CKD for adult patients.^{1–5} The hereditary type
5 IV collagen disease Alport syndrome (AS), is the most common monogenetic glomerular
6 kidney disease.^{6–8} Patients living with AS may develop CKD early in life. The disruption of
7 type IV collagen structure in AS leads to a dysfunction of the basement membrane filtration
8 barrier of the glomeruli with initial micro-hematuria, microalbuminuria and, with disease
9 progression, overt proteinuria, finally progressing to kidney failure (KF), and can be
10 accompanied by hearing loss and ocular lesions.^{9–12} The majority of patients with AS have an
11 X-linked (*COL4A5* gene) inheritance, while up to 30% have an autosomal (*COL4A3* or *COL4A4*
12 genes) inheritance.^{13–15} If started early, therapy with inhibitors of the renin-angiotensin system
13 (RASi) can delay renal failure by years, however, many patients still reach KF at a relatively
14 young age. Therefore, new therapy options are needed.

15 SGLT2i have been approved for the treatment in adults with any kind of CKD in many
16 countries, which is why SGLT2i are also prescribed increasingly for patients with AS.¹⁶ In
17 previous RCTs, the nephroprotective effects of SGLT2i were examined primarily in patients
18 with diabetic kidney disease or other more common causes of non-diabetic CKD. Whether the
19 use of SGLT2i is safe and effective in patients with AS (and thus a different pathogenesis than
20 other CKDs) has not yet been investigated specifically in larger cohorts.^{17–20} Therefore, this
21 international, multi-center, observational, non-interventional study investigated potential side
22 effects of SGLT2i in patients with AS and possible nephroprotective effects using the change
23 in albuminuria and estimated glomerular filtration rate (eGFR) as surrogate parameter for
24 CKD-progression.²¹

Methods

Study population

This multi-center, observational study included a total of 112 patients with AS, who started therapy with SGLT2i. Patients from nine countries and 21 study sites were recruited from 2021 to 2023. The presentation of this study's design at the International Workshop on Alport Syndrome 2021 led to the recruitment of potential study sites.²² Some patients were followed retrospectively (n=99) and others prospectively (n=13). The diagnosis of AS was confirmed genetically or by kidney biopsy (patient or affected relative). Patients living with X-linked, autosomal recessive or autosomal dominant AS were included. Patients were not included if they received kidney transplantation, were on dialysis or did not wish to contribute. Data were pseudonymized at the study site or, in the UK, by the National Registry of Rare Kidney Diseases (RaDaR, for which all patients provided written informed consent with ethical approval provided by NHS South West—Central Bristol Research Ethics Committee (14/SW/1088)). The registry and data storage, in conformity with Good Clinical Practice guidelines, were approved by the Ethics Committee of the University Medical Center Göttingen as part of the European Alport Therapy Registry (AZ 10/11/06; renewed version in 2014 and 2020; ClinicalTrials.gov identifier NCT 02378805).

Intervention and outcome measures

This non-interventional study explored the intra-individual treatment effects of SGLT2i (in most patients on top of RASi). A standardized questionnaire was used as Case Report Form (CRF) to obtain data on demographic parameters, medication, blood and urine test results as well as possible side effects. The study protocol and CRF were approved by the local ethics committee and are provided as supplemental material. Exchange of pseudonymized data was

secured by individual contracts (data processing and cooperation agreements) between the participating centers. All investigators, who contributed data, vouch for the completeness and accuracy of the data set and analyses, and for the fidelity of the study to the protocol. The decision to submit the manuscript for publication was made by all the authors.

Baseline was defined as start of therapy with SGLT2i. The study's primary endpoint was change of albuminuria in mg/g creatinine six month after baseline. If albuminuria was not available, proteinuria was analyzed.²³ Considering the different local standards of measurement, percentage changes from baseline were calculated for overall comparison in patients with overt proteinuria. Additional analyses were performed approximately 3 months after baseline, one year after baseline and, if available, at individual's longest follow up (up to 32 month). Additional analysis included demographic parameters, change of body mass index (BMI), blood pressure and renal function [estimated glomerular filtration rate (eGFR)]. Patients younger than 18 years of age (n=10) were analyzed separately. In children, the CKiD U25 formula could not be used as cystatin c was not available, therefore the Schwartz formula was used to calculate eGFR.

Statistical methods

Statistical comparisons were not formally powered or prespecified. Continuous variables were presented as mean and standard deviation (SD) or as median and inter-quartile range (IQR), categorical variables as frequencies (percentages). For intra-individual comparison of continuous outcomes, a paired t-test was used. To study subgroups, comparison of means between groups was conducted with the unpaired Student's t-test. If equal variances were not assumed, the Welch test was used for group comparison. Pearson's correlation was performed to assess correlations. Probability values (p values) below 0.05 were considered statistically

- 1 significant. Data analyses were performed with IBM SPSS Statistics (version 28 for MacOS,
- 2 IBM Corporation, Armonk, NY, USA).

Results

The duration of therapy in this observational study with SGLT2i in 112 patients with AS added up to a total of 82 patient-years on SGLT2i. Mean follow up time was 9 ± 7 month. At baseline, mean age was 36 ± 15 years, mean eGFR was 68 ± 38 ml/min/1.73m² (n=108) and mean albuminuria was 1689 ± 1455 mg/g creatinine (n=53). Most patients were treated with dapagliflozin (107/112; 96%) and 5 patients were treated with empagliflozin (4%).

Adult patients

Baseline characteristics at initiation of SGLT2i therapy

Table 1 shows baseline characteristics from the 102 adult patients with AS. The mean age at baseline was 38 ± 14 years. The majority of patients were Caucasian (80%) and most patients (63/96; 66%) were male. Diagnosis of AS was confirmed by biopsy in 16 patients (17%), by genetic testing in 51 patients (53%) and by both in 29 patients (30%) (n=96). In 6 patients, it was not reported, how diagnosis was secured. The mode of inheritance was reported in 88 patients (86%). In these patients, 58 patients had X-linked AS (66%), 29 patients had autosomal AS (including autosomal dominant and autosomal recessive AS) (33%) and one patient had AS with diegenic heterozygous variants in the *COL4A3* and *COL4A5* genes (1%). Most adult patients (95/102; 93%) were treated with RASi. Of those, 45 patients (47%) were treated with angiotensin-converting enzyme inhibitors (ACEi), 42 patients (44%) were treated with angiotensin receptor blockers (ARB) and eight patients (8%) were treated with both. Hearing loss was reported in 15 patients (16%; n=93). Most frequent comorbidities were hypercholesterolemia (36/89; 40%), high blood pressure (33/88; 38%), hyperuricemia (25/88; 28%) and vitamin D deficiency (17/88; 19%). The mean BMI was 27 ± 6 kg/m² (n=77), 19 patients

were obese (19/77; 25%). Mean eGFR was 63 ± 35 ml/min/1.73 m² (n=98) and mean albuminuria was 1699 ± 1472 mg/g creatinine (n=51).

First follow up after one to three month(s) (V1)

At a mean time on SGLT2i-therapy of 2 ± 1 months, 67 of the 102 patients (66%) had their first follow up after initiation of treatment. Mean age in these patients was 38 ± 16 years (n=66). Albuminuria was measured in 30 patients and significantly decreased from 1797 ± 1600 mg/g creatinine to 1197 ± 978 mg/g creatinine (p=0.002) (Figure 1A). Proteinuria was measured in 17 patients and decreased from 1101 ± 1119 to 766 ± 857 mg/L (p=0.067). Serum creatinine significantly increased from 1.7 ± 0.7 to 1.8 ± 0.8 mg/dl (n=64; p<0.001) and, correspondingly eGFR dropped from 58 ± 32 to 55 ± 32 ml/min/1.73 m² (n=62; p=0.004) (Figure 1B). Systolic blood pressure was lower (126 ± 15 vs 123 ± 20 mmHg; p=0.147), while diastolic blood pressure remained similar (77 ± 10 vs 78 ± 11 mmHg; p=0.438) (n=55).

Second follow up after four to eight months (V2)

At a mean time on SGLT2i-therapy of 6 ± 1 months, 74 of 102 patients (73%) had a follow up (V2): albuminuria decreased significantly (1727 ± 1564 vs. 1203 ± 1165 mg/g creatinine; n=33; p=0.01) (Figure 2A) and proteinuria decreased from 1191 ± 1206 to 749 ± 613 mg/L (n=15; p=0.098). Serum creatinine increased significantly from 1.6 ± 0.7 to 1.7 ± 0.9 mg/dL (n=73; p<0.001), and corresponding eGFR dropped from 63 ± 34 to 59 ± 33 ml/min/1.73 m² (n=72; p<0.001) (Figure 2B). Systolic blood pressure was significantly lower at V2 (128 ± 14 vs. 124 ± 13 mmHg; n=51; p=0.029), while diastolic blood pressure remained similar (79 ± 12 vs. 78 ± 11 mmHg; n=51; p=0.369). BMI also remained similar (27 ± 7 vs. 27 ± 7 kg/m²; n=35; p=0.6).

Median reduction of proteinuria or albuminuria was similar in male (n=34) and female patients (n=17) (26%, IQR:68 vs 34%, IQR:81; p=0.795). A non-significant trend towards a higher median reduction of proteinuria or albuminuria was observed in patients with autosomal AS (41% IQR: 105; n=17) than in patients with X-linked AS (27%, IQR:61; n=29) (p=0.531). Furthermore, a non-significant trend towards a higher reduction of albuminuria was observed in patients receiving ARBs (712±876 mg/g creatinine; n=16) than in patients treated with ACEis (338±833 mg/g creatinine; n=14) (p=0.243).

Third follow up after nine to fifteen month (V3)

At a mean time on SGLT2i-therapy of 12±2 months, 38 of the 102 patients (37%) had a follow-up (V3): albuminuria was still significantly lower compared to baseline (1737±1796 vs. 1189±1158 mg/g creatinine (n=22; p=0.032) (Figure 3A). Serum-creatinine increased significantly from 1.6±0.6 to 2±0.8 mg/dl (n=34; p<0.001), and, correspondingly eGFR dropped from 57±30 to 49±28 ml/min/1.73 m² (n=35; p<0.001) (Figure 3B). Mean loss of eGFR was 9±12 ml/min/1.73 m² almost one year after baseline (n=35) and a significant negative correlation between the amount of albuminuria at baseline and the change in eGFR was observed (r=-0.82, p<0.01; n=20) (Figure 4). BMI (27±6 vs. 27±6 kg/m²; n=22; p=0.62) and blood pressure were almost similar (systolic blood pressure: 127±13 vs. 126±16 mmHg; n=26; p=0.827; diastolic blood pressure: 82±12 vs. 81±11 mmHg; n=26; p=0.705).

Longest follow up about 2 years after initiation of SGLT2i-therapy (V4)

In 13 patients, data on a longer follow-up were available (mean follow-up 24±6 month). Albuminuria was still lower compared to baseline (2127±1666 vs. 1903±1371 mg/g creatinine;

n=7; p=0.524). Serum-creatinine increased significantly from 1.3 ± 0.6 to 1.5 ± 0.7 mg/dl (n=11; p=0.04), and corresponding eGFR dropped from 75 ± 46 to 67 ± 42 ml/min/1.73 m² (n=11; p=0.05).

Serum-Albumin as surrogate marker of loss of urine-proteins

At a mean follow up of 12 ± 2 month after initiation of SGLT2i-therapy, serum-albumin increased significantly from 3.7 ± 0.7 to 4.0 ± 0.4 g/dL (n=18; p=0.019). The change in serum-albumin in patients with hypoalbuminemia at baseline was calculated and a relevant increase was observed: serum-albumin increased from 3.1 ± 0.4 to 3.4 ± 0.3 mg/dL after a mean follow up of 9 ± 7 month after baseline (n=17; p=0.06). Out of 17 patients with hypoalbuminemia at baseline, 8 (47%) recovered to serum-albumin levels within the normal range at follow up.

Course of eGFR

A total of 16 patients had a follow-up at every single predefined visit. In these patients, a similar decrease of eGFR compared to the overall cohort was observed (55.1 ± 22.8 ml/min/1.73 m² to 46.3 ± 19 ml/min/1.73 m²; p=0.02) (Figure 5).

Genotype phenotype correlation

To investigate a possible influence of the genotype, male patients with XLAS were divided in two groups depending on their pathogenic variant causing AS. Out of 28 patients, 17 (61%) had missense variants and 11 (39%) patients had non-missense variants (defining a faster progression of their CKD). At baseline, patients with missense variants were older (35 ± 12 years; n=16 vs. 27 ± 9 years; n=11), had a significant lower eGFR 63 ± 33 (n=16) vs. 92 ± 32 ml/min/1.73 m² (n=11) and a higher median amount of albuminuria of 1865 (IQR: 2442; n=11) vs. 750 (IQR: 763; n=5) mg/g creatinine. Of note, despite the higher amount of albuminuria at

baseline, at V2 after a mean follow up of 6 month, a significantly higher loss of eGFR was observed in patients with non-missense variants (13 ± 9 ml/min/ 1.73 m²; n=16) than in patients with missense variants (4 ± 9 ml/min/ 1.73 m²; n=11) ($p=0.023$). In parallel, median amount of albuminuria decreased in patients with missense variants from 1865 (IQR: 2442) to 775 (IQR: 1615) mg/g creatinine, while median amount of albuminuria increased in patients with non-missense variants to 1086 (IQR: 450) mg/g creatinine.

Children

Table 2 shows the baseline characteristics and follow-up data from the 10 children in this study. All children were treated with an ACEi. Hearing loss was reported in 3 patients (30%). One patient had also hypercholesterolemia and vitamin D deficiency. In one patient hyperglycemia was reported.

At baseline, mean age was 15 ± 3 years (range: 9 – 17 years), mean BMI was 21 ± 4 kg/m². The mean longest follow-up time was 4 ± 5 months. Serum-creatinine increased from 0.8 ± 0.3 to 0.9 ± 0.3 mg/dL and eGFR decreased from 119 ± 32 to 107 ± 34 ml/min (n=10). In most patients, proteinuria was measured in mg/dl (n=8) and increased slightly (114 ± 94 vs 122 ± 110 mg/dL). Interestingly, in the two patients with already overt proteinuria, in which albuminuria was measured, albuminuria decreased from 1426 ± 1247 to 641 ± 190 mg/g creatinine. Blood pressure remained similar ($116 \pm 13/72 \pm 11$ vs $117 \pm 13/71 \pm 13$ mmHg; n=8).

Safety

Data on adverse events (AEs) were reported in 89 patients (79%). At a total of 71 patient-years at risk (mean time on therapy was 10 ± 7 months), 0.24 AEs per patient year on SGLT2i were reported. In 72 patients (81%), there were no AEs reported (Figure 6A). The AEs in the

remaining 17 patients (18%) included impairment of kidney function (n=7, in one patient during a severe infection with SARS-CoV-2), headache (n=2), hypovolemia (n=1), one bone-fracture (bike accident), genital infection in one female and one patient reported an unwanted loss of weight. A 33 year-old female was hospitalized because of an acute necrotizing pancreatitis two years after therapy with SGLT2i was started. A 33 year old male with XLAS received a kidney transplantation five month after SGLT2i was started. One 44 years old male with compound heterozygous autosomal AS and an eGFR of 27 ml/min/1.73 m², when SGLT2i was started, reached KF nine month later. Ketoacidosis or major hypoglycemic events were not reported. The most severe AE was observed in a male without diabetes, who developed Fournier's gangrene after 23 months of treatment with SGLT2i.²⁴ In brief, this life-threatening situation developed within hours, requiring emergency wound debridement. During his stay on the intensive care unit, the patient developed an acute on chronic kidney injury AKIN III, however, kidney function recovered to baseline. The patient slowly recovered with sequelae. Data on discontinuation of therapy were available in 106 patients (95%). Therapy was discontinued in 9 patients (8%) (Figure 6B). Mean time to discontinuation of therapy was 10±8 month (Figure 6C). Therapy was discontinued due to increase of creatinine (n=1) or polyuria (n=1). In two patients, SGLT2i was discontinued due to impairment of kidney function and was restarted after infusion therapy. The patient with unwanted weight loss decided to pause therapy for a few months and restarted therapy with SGLT2i. Therapy was stopped permanently in the patient with the Fournier's gangrene and the patient with acute necrotizing pancreatitis. In one patient, the reason for discontinuation was not reported. In the 10 children of our study, there were no AEs observed and the treatment with SGLT2i was not discontinued.

1 Discussion

2 This worldwide, observational study investigated a cohort of patients with AS, who started
3 therapy with SGLT2i, including 10 children. The primary endpoint was change of albuminuria
4 after six months on therapy. The primary mechanism by which SGLT2is are considered to be
5 nephroprotective is afferent vasoconstriction and reduction in intraglomerular pressure due
6 the tubuloglomerular feedback via the macula densa.^{25,26} A marker of this reduction is a
7 decrease in the amount of albuminuria, which is largely independent of concomitant changes
8 in metabolic parameters or eGFR.²⁷ Notably, a 25% decrease in albuminuria has been reported
9 to provide confidence that an intervention would result in a clinical benefit.²⁸ In the adult
10 patients of this study, at the first three follow-up visits after initiation of SGLT2i-therapy, a
11 consistent and significant reduction of albuminuria by >30% was observed. This can be
12 interpreted as promising signal that the reduction of albuminuria in these patients might result
13 in clinical benefit at longer follow-up. Importantly, this study showed a significant correlation
14 between the amount of albuminuria at baseline and the later change of eGFR in patients with
15 AS. Patients with truncating gene-variants causing AS are less responsive to RASi-therapy.²⁹
16 This study indicates that AS patients with non-missense variants might also be less responsive
17 to SGLT2i-therapy than patients with missense variants, as a significant higher loss of eGFR
18 was observed in AS patients with non-missense variants in this study. Therefore, future
19 studies investigating SGLT2i in AS should consider stratifying by genotype.

20 At baseline, a relevant number of patients had a hypoalbuminemia. In agreement with the
21 decrease of albuminuria after start of SGLT2i-therapy, 47% of the patients with
22 hypoalbuminemia at baseline recovered to a normal serum-albumin at follow-up. One can
23 speculate that the positive effect of SGLT2i-therapy on lowering albuminuria contributed to
24 the increase in serum-albumin though regression to the mean over the course of this study

cannot be ruled out. Therefore, SGLT2i might be considered as an additional treatment option in patients with AS and hypoalbuminemia due to nephrotic range albuminuria. Approximately one year after baseline, a significantly decrease in the eGFR of -9 ± 12 ml/min/1.73 m² per year was observed. SGLT2i can cause an acute transient decrease in eGFR through a reduction in glomerular pressure.³⁰ For that reason, the decrease in eGFR observed in this study is thought to be – in parts – triggered by the initiation of SGLT2i-therapy. However, the change in eGFR in this study appears to be higher compared to previously described changes in eGFR in other glomerular diseases: eGFR changed by -3.7 and -3.5 mL/min/1.73 m²/year in patients with focal segmental glomerulosclerosis and IgA nephropathy.^{31,32} Due to the observational nature of this study, the change in eGFR is not placebo-controlled. While this limitation should be acknowledged, patients with AS need to be recognized a high-risk group for fast CKD-progression.³³ SGLT2is are, irrespective of hypertension status, associated with a slight reduction in blood pressure mediated through natriuresis, reduction in arterial stiffness and improvement in endothelial function.^{34–37} In this study, systolic blood pressure was significantly lower at V2 (128 ± 14 vs. 124 ± 13 mmHg). However, this difference was not observed after a longer follow-up, possibly due to the small number of patients remaining at that time point. The slight decrease of blood pressure might contribute to the nephroprotective effect of SGLT2is. Reducing glomerular filtration pressure can alleviate proteinuria and subsequent renal tubular and interstitial damage.^{6,11,38} Therefore, preventing angiotensin II-mediated constriction of the efferent arteriole by RASi is the cornerstone of antiproteinuric therapy to reduce podocyte injury in AS.^{39,40} SGLT2i are expected to have an additive effect on the glomerulus via afferent arteriole constriction. Therefore, combining RASi with SGLT2i in patients with albuminuria due to glomerular disease is anticipated to enhance kidney failure-free timespan.⁴¹ Although

the precise mechanisms underlying preservation of kidney function by SGLT2i are not fully understood, other proposed pathways include inflammation and fibrosis suppression as well as a reduction in renal ischemia.^{42,43}

Therapy with SGLT2i was overall well tolerated with a relatively low rate of discontinuation of therapy or reported adverse events. Adverse events related to hypovolemia, which were reported to be more common in patients treated with SGLT2i, was observed in one patient.⁴⁴

Ketoacidosis or severe hypoglycemia were not observed, but two severe adverse events (acute necrotizing pancreatitis and Fournier's gangrene) occurred. Due to the relevant loss of eGFR and severe adverse events observed in this study (though a relationship between SGLT2i and these events is uncertain), a cautious approach is currently recommended when administering SGLT2 inhibitors to patients with AS. Furthermore, this underscore the importance of generating further high-level evidence for efficacy and safety when SGLT2i are prescribed in rare disease like AS, at early stages of CKD or in young patients, especially children, as these groups were not well represented in the previous RCTs. Therefore, the multicenter, randomized, double-blind, placebo-controlled, trial DOUBLE PRO-TECT Alport trial (NCT05944016) will assess safety and efficacy of the SGLT2i Dapagliflozin in children and young adults with AS. Eligible patients will be 2:1 randomly assigned to 48 weeks of treatment with Dapagliflozin or placebo. The primary endpoint will be change in UACR and, as key secondary outcome, eGFR change will be analyzed.⁴⁵

This study had limitations that warrant cautious interpretation of the results: Due to the observational nature of this study, the timing of UACR and eGFR assessments after treatment initiation were not standardized and changes in eGFR and UACR were not placebo-controlled. The retrospective design also limits the ability to comprehensively assess the safety profile of SGLT2i in patients with AS. While the lack of a control arm limits the generalizability of the

1 study findings, including one might have posed challenges in interpretation. Patients in a
2 control arm would likely have a more stable disease course compared to those who opted for
3 a new treatment option. This inherent selection bias would have complicated the analysis of
4 treatment effects. Therefore, the study design focused on intra-individual changes in eGFR
5 and UACR to assess treatment response. Conversely, this approach introduces a potential
6 selection bias of its own, with a possible overrepresentation of patients with a higher risk of
7 CKD progression. Furthermore, only a small number of children and adolescents could be
8 included in the study, the observation period for these patients was relatively short, and due
9 to the unavailability of Cystatin C, the CKiD U25 formula could not be used. Additionally, for
10 six patients, the method used to confirm the diagnosis was not provided.

11 Despite these limitations, this study provides first evidence for a possible nephroprotective
12 effect of SGLT2i in patients with AS by including a substantial number of patients with AS,
13 considering the rarity of the disease and the recent approval of SGLT2i for CKD, and formed
14 the scientific basis for the current RCT with SGLT2i in children and young adults with AS,
15 *DOUBLE PRO-TECT Alport*.

1 **Conclusions**

2 In conclusion, this study indicates that, additive to RASi, SGLT2i have the potential to reduce
3 the amount of albuminuria in patients with Alport syndrome. This study successfully formed
4 the scientific basis for the current RCT with SGLT2i in children and young adults with AS,
5 *DOUBLE PRO-TECT Alport*. Future studies are needed to investigate the long-term effects of
6 SGLT2i on CKD progression in patients with AS to assess whether the observed reduction in
7 albuminuria translates to a delay in kidney failure.

8

9

10

1 DISCLOSURE

2 JB, OG, TF and JS are members of the steering committee of the DOUBLE PRO-TECT Alport
3 trial. OG received advisory fees from AstraZeneca, his employer received advisory fees from
4 Boehringer Ingelheim. MH has received speaker fees from AstraZeneca. The other authors
5 declare no conflicts of interest.

6 DATA STATEMENT

7 After de-identification, individual participant data that underlie the results reported in this
8 article will be shared to investigators whose proposed use of the data has been approved by
9 an independent review committee identified for this purpose. The full study protocol is
10 provided as supplement. Requests should be sent to the corresponding author.

11 ACKNOWLEDGEMENTS

12 The authors thank all patients and research staff for their participation and assistance in this
13 study.

14 FUNDING

15 This research was funded by Research program, University Medical Center, University of
16 Göttingen. The funder had no role in the study design, data collection, data analysis, data
17 interpretation or writing of the manuscript.

18

19 **Author Contributions:** JB wrote the first draft of the article and contributed to data analysis,
20 data interpretation, content and design of all figures, discussion of the results and manuscript.
21 OG contributed as initiator and head principal investigator of the trial, had access to and
22 assessed the final data and critically revised the manuscript. TF critically revised the
23 manuscript and contributed to data analysis, data interpretation and discussion of the results
24 and the manuscript. DPG, JS, JD, YZ, CB, ANT, MH, JAS, SS, HGK, ACK, VG, KC, BK, JF, UW,

1 MC, MS, RUM, PT, BH, MZ, BK and JH contributed to data collection, data interpretation, and
2 discussion of the results and the manuscript. All authors edited and approved the final version
3 of the article.

4
5
6

7 **Supplementary Material:**

8 Supplementary Material
9 STROBE Checklist
10 Guard Alport study protocol
11 Questionnaire
12 Supplementary information is available at KI Report's website.

References

1. Staplin N, Haynes R, Judge PK, et al. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. *Lancet Diabetes Endocrinol.* 2024;12(1):39-50. doi:10.1016/S2213-8587(23)00321-2
2. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816
3. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. *JAMA Cardiol.* 2021;6(2):1-11. doi:10.1001/jamacardio.2020.4511
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med.* 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med.* 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
6. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's Syndrome, Goodpasture's Syndrome, and Type IV Collagen. *N Engl J Med.* 2003;348(25):2543-2556. doi:10.1056/NEJMra022296
7. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic Utility of Exome Sequencing for Kidney Disease. *N Engl J Med.* Published online December 26, 2018. doi:10.1056/NEJMoa1806891
8. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV $\alpha345$: a position paper of the Alport Syndrome Classification Working Group. *Kidney Int.* 2018;93(5):1045-1051. doi:10.1016/j.kint.2017.12.018
9. Barker DF, Pruchno CJ, Jiang X, et al. A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. *Am J Hum Genet.* 1996;58(6):1157-1165.
10. Boeckhaus J, Strenzke N, Storz C, Gross O. Characterization of Sensorineural Hearing Loss in Children with Alport Syndrome. *Life.* 2020;10(12). doi:10.3390/life10120360
11. Kruegel J, Rubel D, Gross O. Alport syndrome—insights from basic and clinical research. *Nat Rev Nephrol.* 2013;9(3):170-178. doi:10.1038/nrneph.2012.259
12. Kashtan CE. Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis. *Pediatr Nephrol.* 2000;14(6):502-512. doi:10.1007/s004670050804
13. Boeckhaus J, Hoefele J, Riedhammer KM, et al. Precise variant interpretation, phenotype ascertainment, and genotype–phenotype correlation of children in the EARLY PROTECT Alport trial. *Clin Genet.* 2021;99(1):143-156. doi:https://doi.org/10.1111/cge.13861
14. Hertz JM, Thomassen M, Storey H, Flinter F. Clinical utility gene card for: Alport syndrome – update 2014. *Eur J Hum Genet.* 2015;23(9):1269-1269. doi:10.1038/ejhg.2014.254
15. Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport Syndrome: Natural History in 195 Families and Genotype- Phenotype Correlations in Males. *J Am Soc Nephrol.* 2000;11(4):649-657. doi:10.1681/ASN.V114649
16. Mabillard H, Sayer JA. SGLT2 inhibitors – a potential treatment for Alport syndrome. *Clin Sci.* 2020;134(4):379-388. doi:10.1042/CS20191276
17. Judge P, Staplin N, Mayne K, et al. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-

- 1 KIDNEY trial. *Lancet Diabetes Endocrinol.* 2024;12(1):51-60. doi:10.1016/S2213-
2 8587(23)00322-4
- 3 18. Song Z ran, Li Y, Zhou X jie, Zhang H. Efficacy of Dapagliflozin in Adult Autosomal
4 Recessive Alport Syndrome. *Kidney Int Rep.* 2022;7(9):2116-2117.
5 doi:10.1016/j.ekir.2022.06.017
- 6 19. Boeckhaus J, Gross O. Sodium-Glucose Cotransporter-2 Inhibitors in Patients with
7 Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a
8 Large-Scale Study. *Cells.* 2021;10(7):1815. doi:10.3390/cells10071815
- 9 20. Liu J, Cui J, Fang X, et al. Efficacy and Safety of Dapagliflozin in Children With Inherited
10 Proteinuric Kidney Disease: A Pilot Study. *Kidney Int Rep.* 2021;0(0).
11 doi:10.1016/j.ekir.2021.12.019
- 12 21. Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate
13 endpoint for progression of kidney disease: a meta-analysis of treatment effects in
14 randomised clinical trials. *Lancet Diabetes Endocrinol.* 2019;7(2):128-139.
15 doi:10.1016/S2213-8587(18)30314-0
- 16 22. Daga S, Ding J, Deltas C, et al. The 2019 and 2021 International Workshops on Alport
17 Syndrome. *Eur J Hum Genet.* 2022;30(5):507-516. doi:10.1038/s41431-022-01075-0
- 18 23. Boeckhaus J, Mohr L, Dihazi H, et al. Ratio of Urinary Proteins to Albumin Excretion
19 Shifts Substantially during Progression of the Podocytopathy Alport Syndrome, and
20 Spot Urine Is a Reliable Method to Detect These Pathologic Changes. *Cells.*
21 2023;12(9):1333. doi:10.3390/cells12091333
- 22 24. Heidegger I, Zwierzina M, Boeckhaus J, Krane V, Gross O. Fournier's gangrene in a
23 patient with CKD without diabetes possibly related to sodium glucose co-transporter 2
24 inhibitor therapy. *Kidney Int Rep.* 2024;0(0). doi:10.1016/j.ekir.2024.02.1404
- 25 25. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia:
26 the pleiotropic effects of SGLT2 inhibition. *Diabetologia.* 2017;60(2):215-225.
27 doi:10.1007/s00125-016-4157-3
- 28 26. Škrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic
29 responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
30 *Diabetologia.* 2014;57(12):2599-2602. doi:10.1007/s00125-014-3396-4
- 31 27. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary
32 albumin-to-creatinine ratio in patients with type 2 diabetes and established
33 cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME
34 randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol.* 2017;5(8):610-621.
35 doi:10.1016/S2213-8587(17)30182-1
- 36 28. Heerspink HJL. Predicting individual treatment response in diabetes. *Lancet Diabetes*
37 *Endocrinol.* 2019;7(6):415-417. doi:10.1016/S2213-8587(19)30118-4
- 38 29. Yamamura T, Horinouchi T, Nagano C, et al. Genotype-phenotype correlations
39 influence the response to angiotensin-targeting drugs in Japanese patients with male X-
40 linked Alport syndrome. *Kidney Int.* 2020;98(6):1605-1614. doi:10.1016/j.kint.2020.06.038
- 41 30. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients
42 With CKD: Expanding Indications and Practical Considerations. *Kidney Int Rep.*
43 2022;7(7):1463-1476. doi:10.1016/j.ekir.2022.04.094
- 44 31. Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD
45 trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients
46 with IgA nephropathy. *Kidney Int.* 2021;100(1):215-224. doi:10.1016/j.kint.2021.03.033
- 47 32. Wheeler DC, Jongs N, Stefansson BV, et al. Safety and efficacy of dapagliflozin in
48 patients with focal segmental glomerulosclerosis: a prespecified analysis of the

- 1 dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-
2 CKD) trial. *Nephrol Dial Transplant*. 2022;37(9):1647-1656. doi:10.1093/ndt/gfab335
- 3 33. Wong K, Pitcher D, Braddon F, et al. Effects of rare kidney diseases on kidney failure: a
4 longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR)
5 cohort. *The Lancet*. 2024;0(0). doi:10.1016/S0140-6736(23)02843-X
- 6 34. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal
7 function and blood pressure. *Diabetologia*. 2018;61(10):2098-2107. doi:10.1007/s00125-018-
8 4669-0
- 9 35. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-
10 regulating drug with diuretic properties in subjects with type 2 diabetes. *Diabetes Obes*
11 *Metab*. 2013;15(9):853-862. doi:10.1111/dom.12127
- 12 36. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial
13 stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes
14 mellitus. *Cardiovasc Diabetol*. 2014;13(1):28. doi:10.1186/1475-2840-13-28
- 15 37. Mazidi M, Rezaie P, Gao H, Kengne AP. Effect of Sodium-Glucose Cotransport-2
16 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic
17 Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. *J Am*
18 *Heart Assoc*. 6(6):e004007. doi:10.1161/JAHA.116.004007
- 19 38. Abrahamson DR, Hudson BG, Stroganova L, Borza DB, John PLS. Cellular Origins of
20 Type IV Collagen Networks in Developing Glomeruli. *J Am Soc Nephrol*. 2009;20(7):1471-
21 1479. doi:10.1681/ASN.2008101086
- 22 39. Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and
23 management of Alport syndrome in children, adolescents, and young adults—an update
24 for 2020. *Pediatr Nephrol*. 2021;36(3):711-719. doi:10.1007/s00467-020-04819-6
- 25 40. Benzing T, Salant D. Insights into Glomerular Filtration and Albuminuria. Ingelfinger
26 JR, ed. *N Engl J Med*. 2021;384(15):1437-1446. doi:10.1056/NEJMr1808786
- 27 41. Vart P, Vaduganathan M, Jongs N, et al. Estimated Lifetime Benefit of Combined RAAS
28 and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes. *Clin*
29 *J Am Soc Nephrol*. 2022;17(12):1754. doi:10.2215/CJN.08900722
- 30 42. Packer M. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in
31 the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics. *Am J*
32 *Kidney Dis*. 2021;77(2):280-286. doi:10.1053/j.ajkd.2020.04.016
- 33 43. Woods TC, Satou R, Miyata K, et al. Canagliflozin Prevents Intrarenal Angiotensinogen
34 Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type
35 2 Diabetes Mellitus. *Am J Nephrol*. 2019;49(4):331-342. doi:10.1159/000499597
- 36 44. Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal
37 events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
38 *PLOS Med*. 2019;16(12):e1002983. doi:10.1371/journal.pmed.1002983
- 39 45. Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R, Gerst C, Duerr U,
40 Walker F, Tostmann R, Helm J, Asendorf T, Friede T for the study group of the German
41 Society of Pediatric Nephrology (GPN). Protocol and rationale for a randomized
42 controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic
43 kidney disease: DOUBLE PRO-TECT Alport. *Nephrol Dial Transplant*, 2024 in press
44
45

Tables:**Table 1:** Demographic and clinical characteristics of the 102 adult patients in GA at baseline.

Values are mean±SD or n(%) as appropriate

ACEi, Angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI,

Body-Mass-Index; RASi, inhibitors of the renin-angiotensin system

	N	
Age (years)	102	38±14
Male no. (%)	96	63 (66)
Ethnicity	88	
Caucasian		68 (80)
Asian		16 (19)
Hispanic		1 (1)
Country (%)	102	
Belgium		6 (6)
China		3 (3)
France		6 (6)
Germany		39 (38)
Lithuania		8 (8)
South Korea		9 (9)
Switzerland		2 (2)
UK		22 (22)
USA		7 (7)
Mode of inheritance (%)	88	
X-linked		58 (66)
Autosomal		29 (33)
Digen		1 (1)
RASi	102	95 (93)
ACEi		45 (47)
ARB		42 (44)
ACEi + ARB		8 (8)
BMI (kg/m ²)	77	27±6
Systolic/diastolic blood pressure (mmHg)	82	127±16/78±11
Albumin (g/dL)	69	3.8±0.5
Creatinine (mg/dl)	101	1.6±0.7
eGFR (ml/min/1.73 m ²)	98	63±35
Albuminuria (mg/g creatinine)	51	1699 ±1472
Proteinuria (mg/g creatinine)	36	1805±1326

Table 2: Baseline characteristics and follow up data after a mean follow up of 4±5 month in 10 children. Values are mean±SD or n(%) as appropriate

	N	Baseline	Follow up
Age (years)	10	15±3	
Male no. (%)	5	5 (50)	
Mode of inheritance (%)	10		
X-linked		9 (10)	
Autosomal		1 (10)	
BMI (kg/m ²)	10	21±4	
Systolic/diastolic blood pressure (mmHg)	8	116±13/72±11	117±13/71±13
Creatinine (mg/dl)	10	0.8±0.3	0.9±0.3
eGFR (ml/min/1.73 m ²)	10	119±32	107±36
Proteinuria (mg/dL)	8	114±94	122±110
Albuminuria (mg/g creatinine)	2	1426±1247	641±190

Figures

Figure 1: Albuminuria and eGFR at V1 (months 1-3)

A Albuminuria before initiation of SGLT2i therapy (baseline; blue) and after a mean follow up of 2 ± 1 months (V1; red) of SGLT2i therapy ($p=0.002$, $n=30$; geometric mean with 95% CI)

B eGFR before initiation of SGLT2i therapy (baseline; blue) and after mean follow up of 2 ± 1 months (V1, red) ($p=0.004$, $n=62$; mean with 95%CI).

Figure 2: Albuminuria and eGFR at V2 (months 4-8)

A Albuminuria before initiation of SGLT2i-therapy (baseline; blue) and after a mean follow up of 6 ± 1 month (V2; red) ($p=0.01$, $n=33$, geometric mean with 95% CI);

B eGFR before initiation of SGLT2i-therapy (baseline, blue) and after a mean follow up of 6 ± 1 month (V2; red) ($p<0.001$, $n=72$, mean with 95%CI).

Figure 3: Albuminuria and eGFR at V3 (months 9-15)

A Albuminuria before initiation of SGLT2i-therapy (baseline; blue) and after a mean follow up of 12 ± 2 month (V3; dark red) ($p=0.032$, $n=22$, geometric mean with 95% CI);

B eGFR before initiation of SGLT2i-therapy (baseline; blue) and after a mean follow up of 12 ± 2 month (V3; dark red) ($p<0.001$, $n=35$, mean with 95%CI).

Figure 4: Correlation between amount of albuminuria at baseline and the change in eGFR after initiation of SGLT2i

Pearson's correlation between amount of albuminuria at baseline and absolute change in eGFR at a mean follow up of 11 ± 2 month ($r=0.821$; $p<0.01$; $n=20$)

Figure 5: Change in eGFR over time after initiation of SGLT2i-therapy

eGFR at baseline, V1 (months 1-3), V2 (months 4-8) and V3 (months 9-15) in 16 patients, who completed every visit from V1 to V3;

Figure 6: Frequency of adverse events and discontinuation of SGLT2i-therapy

- A Number of patients with observed adverse events (AEs) (white) and patients without observed AEs (dark grey) ($n=89$);
- B Number of patients without (therapy continued; white) and with discontinuation of therapy with SGLT2i (therapy discontinued; dark grey) ($n=106$).
- C Time to discontinuation of SGLT2i-therapy in month. The reason for discontinuation in one patient after seven month was not reported.











